(@BamBamInvest) en getquin

1Semana·

Summary of the most exciting parts of yesterday's Investor Day:

1. management is very confident that they can do 10,000 transplants. That is the publicly stated goal, but they have sites that could make far more possible.

2. currently we use less than 20% of lungs, less than 30% of hearts and about 60% of livers. This means that the majority of the donor pool is completely unused.

3. there are many $TMDX (+1,52 %) competitors that do not solve the ischemia problem. Ischemic damage occurs when an organ is not supplied with blood. The longer this lasts, the greater the risk of morbidity. There is no competitor that has a product that can eliminate ischemic damage and get the organ to the patient. $TMDX (+1,52 %) has the only portable multi-organ perfusion technology in the world.

4 $TMDX (+1,52 %) Data shows that it has reduced primary graft dysfunction in lung transplants by 50%, heart and liver by 65% and ischemic biliary complications in liver transplants by 84%.

5. $TMDX (+1,52 %) presented its command center, the heart of the logistics business. This is the place where $TMDX (+1,52 %) coordinates its missions (air and ground) to ensure that organs reach their destination as quickly as possible. It shows how$TMDX (+1,52 %) X has full control over its entire business operations. It is one of the biggest moats for a small-cap company in the entire market.

6. data has shown that ischemic biliary complications in 4,300 liver transplants using $TMDX (+1,52 %) transported organs are only 1.7%.

7. morning transplants are a key factor in the success of organ transplants and finances. Morning transplants have not been possible in the past, but with $TMDX (+1,52 %) logistical possibilities they are now.

8 There are three next-gen programs that will lead to tremendous growth in 2025, all leveraging the large investments in the logistics network in 2024. These are the Next Gen Lung Program, the Next Gen Heart Clinic Program and the NOP Network, which will be a digital ecosystem with full transparency for all stakeholders involved.

9. $TMDX (+1,52 %) have eliminated all edema in lung transplants within 24 hours. This is something they have not yet achieved in 2024. This was communicated to 175 lung transplant surgeons in Boston 2 weeks ago, so it's all very new and an exciting development for 2025.

9 Management also introduced Envision, an ecosystem that manages all aspects from organ procurement to transplantation. It also includes all financial management tasks such as case counts for OCS, OCS costs and automated billing. More rationalization. More efficiency.

10. the management has repeatedly emphasized that $TMDX (+1,52 %) will be an international company. The TAM is huge.

11. the focus of development in 2025 will be on kidneys, with launch in 2029 after FDA clinical trials in 2027. this will add approximately 50,000 transplants to the TAM annually.

12. management discussed its vision for the next generation of OCS, which completely redefines how OCS works in order to $TMDX (+1,52 %) enable the performance of over 30,000 transplants per year. Everything will be highly automated and closely connected to the cloud, resulting in tremendous financial efficiencies.

Conclusion: It all sounds very exciting, the company certainly has potential and enormous growth opportunities, but it will take time and you have to be patient.

BamBamInvest

@BamBamInvest

1Semana·

$TMDX (+1,52 %) - Company presentation - Part 1:

TransMedics Group, Inc. is a medical device company transforming organ transplant therapy for patients with end-stage lung, heart and liver failure.

The company specializes in portable extracorporeal thermal perfusion and the evaluation of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that uses its customized technology to replicate near-physiological conditions for donor organs outside the human body.

In addition, the company has developed the National OCS Program (NOP), a turnkey solution for outsourced organ harvesting, OCS organ management and logistics services for transplant programs in the United States. Logistics services include air transportation, ground transportation and other coordination activities. NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators to provide an end-to-end clinical solution utilizing OCS technology.

Now a little more in detail:

OCS = Organ Care System

$TMDX (+1,52 %) currently has OCS consoles for the heart, liver and lungs.

The cool thing about $TMDX (+1,52 %) 's OCS is that normally 2-3 out of 10 organs stored in the cold room are successfully transplanted.

8 out of 10 OCS organs or disposable sets (as they are called) are transplanted without complications.

The trick lies in the ability of the $TMDX (+1,52 %) OCS console to maintain organ functionality through the constant circulation of warm blood (perfusion).

The OCS consoles are the only FDA-approved portable multi-organ perfusion device on the market.

The installation of these innovative cutting-edge consoles in the 70 leading transplant centers in the USA is probably equivalent to a monopoly position.

Blood flow to the organs and constant monitoring of their functionality reduces ischemic injury and post-transplant complications.

$TMDX (+1,52 %) also has its own fleet of 18 airplanes to help get organs to where they are needed.

If an organization needs to outsource the pick-up or drop-off of organs, it can use an aircraft from the NOP network. $TMDX (+1,52 %) - aircraft from the NOP network.

NOP = National OCS Program

The NOP's nationwide hub network takes care of the transportation of organs from the donor to the recipient around the clock

The NOP network has now contributed to over 4,000 transplants

This is the only air and ground network that is 100% dedicated to the transportation of organs.

Business model:

Selling organs and organ care system (OCS) consoles to organ transplantation and procurement centers and organizations, as well as selling to distributors who sell their products to centers and organizations abroad.

Service:

They also sell organ procurement and organ management services to all of these organizations through NOP

All customer contracts include multiple performance obligations covering all products and services they provide (organs, OCS, NOP services).

Financials:

Annual revenue:

2021: $30.3M

2022: $93.5M

2023: $241.6M

2024: $434.1M est +79% YoY

2025: $548.1M est +26%YoY

EPS - a strong increase is expected:

2023: -$0.77

2024: USD 1.07 estimated

2025: estimated USD 1.65

$TMDX (+1,52 %) is managed by the founder - which should be an advantage.

Since 1998, the CEO has built this company into the country's leading transplant network.

CEO- Waleed Hassanein

$TMDX (+1,52 %) is still a small cap and

basically has everything it takes to become a future monopoly.

Best product of its kind
Building a complex logistics network before anyone else does
Only FDA approved product of its kind

$TMDX (+1,52 %) Continues to invest heavily in the future

They addressed profit margins and stated that they continue to invest in hiring pilots, aircraft, maintenance centers - to take care of their own aircraft, etc.

All these investments will $TMDX (+1,52 %) probably turn the company from a small-cap to a mid-cap in the next few years.

The weakness in earnings in recent earnings is probably not fundamentally due to the weakness of the company.

The quarter-on-quarter decline in sales was due to general weakness and maintenance measures in the industry as well as investments that affect margins and apparently surprised many analysts.

There is actually nothing wrong with the business.

Finally, I would like to say that I am not yet invested, but after the recent fall in the share price, a long-term entry should be very interesting and I am considering an initial entry.

Are any of you already invested? ✌️